Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event
Autonomix Medical (NASDAQ: AMIX) announced its participation in the Virtual Investor Closing Bell Series scheduled for May 22, 2025, at 4:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) announced its participation in the Virtual Investor Closing Bell Series scheduled for May 22, 2025, at 4:00 PM ET. During the event, CEO Brad Hauser will provide a corporate overview and discuss the company's innovative catheter-based microchip sensing array technology. This first-in-class platform system aims to enhance neural signal detection and differentiation compared to existing technologies.
The event will include a live interactive Q&A session where investors can submit questions. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days following the event.
Details
News Market Reaction – AMIX
The recorded move for AMIX in the trading session of this news was -5.95%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live webcast followed by an interactive Q&A session on Thursday, May 22nd at 4:00 PM ET
Access the event here
THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the Virtual Investor Closing Bell Series on Thursday, May 22, 2025 at 4:00 PM ET.
As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, will provide a corporate overview and discuss the Company’s first-in-class platform system technology, a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. In addition, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
The live video webcast will be available on the Events page under the Investors section of the Company’s website (autonomix.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
(908) 824-0775
autonomix@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.